Rivoceranib is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Upon administration, rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. Additionally, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases. It is grouped under the following drug class(es): Tyrosine Kinase Inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include rivoceranibum and Apatinib. Its PubChem CID is 11315474.
Rivoceranib
| CAS No | 811803-05-1 |
|---|---|
| Molecular Formula | C24H23N5O |
| Molecular Weight | 397.5 g/mol |
| Synonyms | N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Rivoceranib is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities.
The listed CAS number is 811803-05-1.
The listed molecular formula is C24H23N5O.
The listed molecular weight is 397.5 g/mol.
N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide.
The source lists rivoceranibum and Apatinib.